Alameda, California | April 13, 2026
Penumbra, Inc. has announced compelling 90-day results from the STORM-PE randomized controlled trial, demonstrating that computer-assisted vacuum thrombectomy (CAVT™) combined with anticoagulation significantly improves functional outcomes in patients with acute intermediate-high risk pulmonary embolism (PE) compared to anticoagulation alone. The study, presented at the Society of Interventional Radiology (SIR) Annual Scientific Meeting 2026, revealed that patients treated with CAVT achieved superior mobility, improved quality of life, and higher rates of functional recovery, marking a major advancement in endovascular therapy for life-threatening cardiovascular conditions.
STORM-PE Trial Demonstrates Superior Functional Recovery
The STORM-PE trial, a prospective, multicenter randomized controlled study involving 100 patients across 22 international sites, evaluated the effectiveness of Penumbra’s Lightning Flash™ thrombectomy system combined with standard anticoagulation therapy. At 90 days, patients receiving CAVT demonstrated significantly greater improvements in functional capacity, including walking distances of 479 meters compared to 368 meters in the anticoagulation-only group.
Additionally, 97% of patients achieved New York Heart Association (NYHA) Class I status, indicating no physical limitations, compared to 76% in the control group. These results highlight the clinical superiority of CAVT in restoring patient mobility and functional independence, which are critical endpoints in pulmonary embolism recovery.
AI-Powered eloAI Transforms Data Insights and Decision-Making
Advertisement
A standout feature of Elosity R3 is the expansion of eloAI, the platform’s built-in artificial intelligence engine, which allows clinical teams to interact with trial data using natural language queries. This innovation enables users to quickly generate real-time insights, visualizations, and operational analytics, significantly reducing the time required to analyze complex datasets. By integrating AI directly into the RTSM platform, Endpoint Clinical empowers teams to move from data collection to actionable insights faster, improving responsiveness and decision-making. Importantly, the system maintains study blinding, role-based access controls, and regulatory compliance, ensuring that data integrity and confidentiality are preserved. This combination of AI-driven intelligence and compliance-focused design represents a major advancement in clinical trial technology.
Advanced Thrombectomy Technology Enhances Patient Outcomes
Penumbra’s computer-assisted vacuum thrombectomy (CAVT) technology utilizes dual clot detection algorithms and high-powered aspiration mechanisms to effectively remove blood clots from the pulmonary vasculature. This advanced system allows for rapid reperfusion and improved right ventricular recovery, addressing the underlying pathophysiology of pulmonary embolism more directly than anticoagulation alone.
The study also showed that patients treated with CAVT achieved near-normalized walking capacity (94% of predicted distance) compared to 75.2% in the control group, underscoring the therapy’s ability to restore physiological function and exercise tolerance. These findings reinforce the role of minimally invasive, device-based interventions in modern cardiovascular care.
Favorable Safety Profile Supports Broader Clinical Adoption
Importantly, the STORM-PE study confirmed that the addition of CAVT did not compromise patient safety. The trial reported no device-related mortality, no increase in pulmonary embolism recurrence, and comparable safety outcomes between treatment groups over the 90-day period. These results demonstrate that CAVT offers a balanced benefit-risk profile, combining enhanced efficacy with maintained safety standards. As pulmonary embolism remains a leading cause of cardiovascular mortality worldwide, the availability of safe and effective interventional therapies is critical for improving patient outcomes and reducing long-term complications.
Implications for Future Treatment Guidelines and Clinical Practice
Pulmonary embolism affects approximately 900,000 individuals annually in the United States, representing a major healthcare burden. The STORM-PE findings provide robust clinical evidence supporting the integration of endovascular therapies into standard treatment protocols, particularly for patients with intermediate-high risk PE. The study’s emphasis on patient-centered outcomes, such as mobility and quality of life, aligns with evolving clinical priorities in cardiovascular care. Additionally, ongoing studies such as STRIKE-PE are expected to further validate the long-term benefits of CAVT, potentially influencing future clinical guidelines and treatment strategies.
The STORM-PE trial results position Penumbra’s CAVT technology as a transformative advancement in the treatment of pulmonary embolism, offering significant improvements in functional recovery, patient mobility, and overall quality of life. With strong clinical evidence, a favorable safety profile, and growing adoption of minimally invasive therapies, CAVT has the potential to redefine treatment standards for PE. As healthcare continues to prioritize precision, efficiency, and patient-centered care, innovations like Penumbra’s thrombectomy system are set to play a pivotal role in the future of interventional medicine.
Source: Penumbra press release
